» Articles » PMID: 37176696

Narrative Review: Low-Dose Ketamine for Pain Management

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 May 13
PMID 37176696
Authors
Affiliations
Soon will be listed here.
Abstract

Pain is the leading cause of medical consultations and occurs in 50-70% of emergency department visits. To date, several drugs have been used to manage pain. The clinical use of ketamine began in the 1960s and it immediately emerged as a manageable and safe drug for sedation and anesthesia. The analgesic properties of this drug were first reported shortly after its use; however, its psychomimetic effects have limited its use in emergency departments. Owing to the misuse and abuse of opioids in some countries worldwide, ketamine has become a versatile tool for sedation and analgesia. In this narrative review, ketamine's role as an analgesic is discussed, with both known and new applications in various contexts (acute, chronic, and neuropathic pain), along with its strengths and weaknesses, especially in terms of psychomimetic, cardiovascular, and hepatic effects. Moreover, new scientific evidence has been reviewed on the use of additional drugs with ketamine, such as magnesium infusion for improving analgesia and clonidine for treating psychomimetic symptoms. Finally, this narrative review was refined by the experience of the Pain Group of the Italian Society of Emergency Medicine (SIMEU) in treating acute and chronic pain with acute manifestations in Italian Emergency Departments.

Citing Articles

Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials.

Abu-Hussein B, Elrosasy A, Samy H, Ali A, Alijla S, Bitar A Clin Transl Oncol. 2025; .

PMID: 39907885 DOI: 10.1007/s12094-025-03847-8.


Investigating Strategies to Enhance the Aqueous Solubility of Ketamine HCl for Intranasal Delivery.

Idoudi S, Saleh A, Akkbik M, Amine L, Alansari K, Rachid O Pharmaceutics. 2025; 16(12.

PMID: 39771482 PMC: 11677332. DOI: 10.3390/pharmaceutics16121502.


Effect of subanesthetic dose of esketamine on early postoperative depression in elderly patients with Sarcopenia.

Fang Y, Cao G, Hu S, Cheng J, Wang Y J Orthop Surg Res. 2024; 19(1):881.

PMID: 39725976 PMC: 11670516. DOI: 10.1186/s13018-024-05388-2.


Characterization of the temporal profile of the antinociceptive effects of an intravenous bolus of ketamine using the analgesia nociception index in no-anesthetized adult patients.

Navarrete V, Ibacache M, Contreras V, Cortinez I J Clin Monit Comput. 2024; .

PMID: 39546215 DOI: 10.1007/s10877-024-01240-4.


propofol permeation across nasal mucosa: A proof-of-concept study for outpatient light sedation via nasal route.

Spampinato M, Costanzini A, De Giorgio R, Passaro A, Realdon N, Bortolotti F ADMET DMPK. 2024; 12(5):759-768.

PMID: 39524221 PMC: 11542715. DOI: 10.5599/admet.2403.


References
1.
Zhao J, Wang Y, Wang D . The Effect of Ketamine Infusion in the Treatment of Complex Regional Pain Syndrome: a Systemic Review and Meta-analysis. Curr Pain Headache Rep. 2018; 22(2):12. DOI: 10.1007/s11916-018-0664-x. View

2.
Coppel D, Bovill J, Dundee J . The taming of ketamine. Anaesthesia. 1973; 28(3):293-6. DOI: 10.1111/j.1365-2044.1973.tb00449.x. View

3.
Lauritsen C, Mazuera S, Lipton R, Ashina S . Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016; 17(1):106. PMC: 5120050. DOI: 10.1186/s10194-016-0700-3. View

4.
Abbadie C, Brown J, Mantyh P, Basbaum A . Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience. 1996; 70(1):201-9. DOI: 10.1016/0306-4522(95)00343-h. View

5.
Miller M, Kruit N, Heldreich C, Ware S, Habig K, Reid C . Hemodynamic Response After Rapid Sequence Induction With Ketamine in Out-of-Hospital Patients at Risk of Shock as Defined by the Shock Index. Ann Emerg Med. 2016; 68(2):181-188.e2. DOI: 10.1016/j.annemergmed.2016.03.041. View